Optiscan Imaging (ASX:OIL)
ASX announcement history & article coverage
Transparent by design.
Announcments by Optiscan Imaging (ASX:OIL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Optiscan Initiates Head and Neck Cancer Study in the US
Optiscan launches U.S. head and neck cancer imaging study to support FDA submissions
Appendix 4G & Corporate Governance Statement
2026 Annual Report
Optiscan advances clinical-stage transition with FDA dossier submission, $17.75m capital raise, and U.S. veterinary market launch
Preliminary Final Report
Optiscan Imaging reports 53% revenue drop and increased loss in FY26, boosted by $17.75M capital raise
Quarterly Activities/Appendix 4C Cash Flow Report
Optiscan advances US FDA submissions and launches InSpecta™ in US veterinary market
Optiscan Signs New Research Agreement for Breast Study
Optiscan initiates US breast cancer imaging study with Mayo Clinic to support FDA submissions
Head and Neck Study Progressing Ahead of Schedule
Optiscan's Head and Neck Cancer Imaging Study Advances Ahead of Schedule
Optiscan Launches InSpecta Device for Veterinary Medicine
Optiscan launches InSpecta™ veterinary imaging device in U.S. after FDA approval
Halfway Mark Reached in Optiscan Breast Cancer Study
Optiscan reaches halfway recruitment milestone in breast cancer imaging study supporting FDA submissions
